04:10
Vedanta Q1: Cons Net Profit -30.4% at Rs615 Cr Vs Rs884 Cr (YoY)
Vedanta Q1: Cons Net Profit -30.4% at Rs615 Cr Vs Rs884 Cr (YoY)
Cons Total Income -15.1% at Rs14, 437 Cr Vs Rs17, 009 Cr (YoY)
Cons EBITDA -15.8% at Rs3, 439.6 Cr Vs Rs4, 087.2 Cr (YoY).
Pidilite Q1: Net Profit +16.1% at Rs272 Cr Vs Rs234.3 Cr (YoY)
Pidilite Q1: Net Profit +16.1% at Rs272 Cr Vs Rs234.3 Cr (YoY)
Total Income +8.6% at Rs1, 692 Cr Vs Rs1, 557.4 Cr (YoY)
Other Income at Rs24.1 Cr Vs Rs13.9 Cr (YoY)
EBITDA +15.2% at Rs394.4 Cr Vs Rs342.3 Cr (YoY)
EBITDA Margin at 23.3% Vs 22% (YoY)
Alembic Pharma Q1 consolidated net profit up 45% (YoY)
Alembic Pharmaceuticals has announced the following Q1 results for the quarter ended June 30, 2016:
Standalone
Net Profit rose by 53.21% to Rs119.74 crore Vs Rs78.15 crore (YoY).
Total Income increased by 20.01% to Rs688.98 crore Vs Rs574.10 (YoY).
Karnataka Bank Q1 net profit up 11% (YoY)
Karnataka Bank Ltd has announced the following Unaudited Standalone results for the quarter ended June 30, 2016:
Net Profit rose by 11.15% to Rs121.54 crore Vs Rs109.34 crore (YoY).
Total Income increased by 6.43% to Rs1434.96 crore Vs Rs1348.17 crore (YoY).
Kesoram plans Rs600 crore capex for tyre, cement divisions
Kesoram Industries is planning to spend around Rs600 crore on capital expenditure in FY2017.
The company has lined up an investments of Rs350 crore for strengthening its tyre business while about Rs250 crore will be pumped in for its cement division.
The Rs600 crore capex would be over and above the Rs500 crore that was already booked for work-in-progress.
Read our more services below:
Nifty Options Tips
CapitalStars Giving 2 Days Free Trial Calls..... Hurry Up
CapitalStars Giving 2 Days Free Trial Calls..... Hurry Up
CapitalStars Financial Research Financial Advisory Services
www.capitalstars.com |T:+91-731-6790000,6669900
0 comments:
Post a Comment